Cartesian Therapeutics Forecast, price target & analysts
Cartesian Therapeutics Target price 2026 - Analyst rating & recommendation
Cartesian Therapeutics Classifications & Recommendation
Cartesian Therapeutics Price Target
| Target Price | $39.78 |
| Price | $7.22 |
| Potential |
450.97%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Cartesian Therapeutics 2027 .
The average Cartesian Therapeutics target price is $39.78.
This is
450.97%
register free of charge
$46.20
539.89%
register free of charge
$16.16
123.82%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Cartesian Therapeutics to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cartesian Therapeutics stock has an average upside potential 2027 of
450.97%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.80 | 0.30 |
| 92.80% | 89.41% | |
| Net Margin | -4,653.57% | -30,474.31% |
| 2,238.81% | 554.86% |
10 Analysts have issued a sales forecast Cartesian Therapeutics 2026 . The average Cartesian Therapeutics sales estimate is
This results in the following potential growth metrics:
9 Cartesian Therapeutics Analysts have issued a net profit forecast 2026. The average Cartesian Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.02 | -3.01 |
| 12.05% | 40.04% | |
| P/E | negative | |
| EV/Sales | 417.30 |
9 Analysts have issued a Cartesian Therapeutics forecast for earnings per share. The average Cartesian Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Cartesian Therapeutics...
Current Cartesian Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Sep 29 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Jun 10 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Jun 09 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jun 09 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | May 27 2026 |
| Needham |
Locked
➜
Locked
|
Locked | May 26 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Sep 29 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Jun 10 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Jun 09 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 09 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
May 27 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
May 26 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
